Johnson & Johnson (NYSE:JNJ) Trading 0.2% Higher

Johnson & Johnson (NYSE:JNJ)’s stock price traded up 0.2% during trading on Monday . The company traded as high as $159.80 and last traded at $159.63. 767,952 shares were traded during trading, a decline of 89% from the average session volume of 7,299,017 shares. The stock had previously closed at $159.39.

Wall Street Analyst Weigh In

Several research firms recently commented on JNJ. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. TD Securities decreased their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. TD Cowen decreased their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, August 5th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Trading Up 0.8 %

The firm has a market capitalization of $388.51 billion, a price-to-earnings ratio of 10.04, a P/E/G ratio of 2.63 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The business has a fifty day moving average price of $152.89 and a 200 day moving average price of $153.09.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.80 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.07%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Institutional Trading of Johnson & Johnson

Several institutional investors have recently made changes to their positions in the business. Innealta Capital LLC acquired a new stake in Johnson & Johnson in the second quarter worth $27,000. Christopher J. Hasenberg Inc bought a new position in Johnson & Johnson during the 1st quarter worth $31,000. WFA Asset Management Corp boosted its holdings in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $44,000. Finally, Disciplined Equity Management Inc. acquired a new position in Johnson & Johnson during the 4th quarter worth about $45,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.